Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.84 +0.3%	$15.51	$9.57 ▼ $30.41	$2.32B	0.93	1.55 million shs	1.92 million shs
BBIO BridgeBio Pharma	$43.50 -1.1%	$38.08	$21.72 ▼ $45.48	$8.35B	1.15	2.51 million shs	2.54 million shs
LNTH Lantheus	$79.19 -1.5%	$82.10	$73.11 ▼ $126.89	$5.56B	0.12	1.02 million shs	707,327 shs
RVMD Revolution Medicines	$36.67 -3.2%	$39.44	$29.17 ▼ $62.40	$7.05B	1.06	1.68 million shs	1.59 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+4.35%	-0.18%	+63.71%	-34.38%
BBIO BridgeBio Pharma	0.00%	-2.57%	+13.17%	+42.50%	+69.66%
LNTH Lantheus	0.00%	-2.80%	-2.87%	-17.01%	+0.41%
RVMD Revolution Medicines	0.00%	+0.24%	-9.95%	+17.83%	-1.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7448 of 5 stars	3.4	2.0	3.4	2.0	2.5	0.0
BBIO BridgeBio Pharma	4.673 of 5 stars	4.5	2.0	3.9	2.3	3.3	0.6
LNTH Lantheus	4.4154 of 5 stars	3.5	1.0	4.2	2.2	2.5	1.9
RVMD Revolution Medicines	4.5603 of 5 stars	4.5	2.0	4.7	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	159.59% Upside
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	35.28% Upside
LNTH Lantheus	3.00	Buy	$130.50	64.79% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	84.30% Upside

Current Analyst Ratings Breakdown

Latest ARWR, RVMD, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	655.10	N/A	N/A	$1.54 per share	10.94
BBIO BridgeBio Pharma	$221.90M	37.22	N/A	N/A	($7.71) per share	-5.64
LNTH Lantheus	$1.53B	3.57	$6.98 per share	11.34	$15.65 per share	5.06
RVMD Revolution Medicines	$11.58M	589.86	N/A	N/A	$13.47 per share	2.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	19.75	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.50	12.55	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest ARWR, RVMD, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BBIO BridgeBio Pharma	N/A	4.57	4.54
LNTH Lantheus	0.49	5.74	5.46
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BBIO BridgeBio Pharma	99.85%
LNTH Lantheus	99.06%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BBIO BridgeBio Pharma	18.20%
LNTH Lantheus	2.00%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

ARWR, RVMD, LNTH, and BBIO Headlines

Recent News About These Companies

Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors

July 6 at 5:18 AM | msn.com

Leerink Partnrs Issues Positive Estimate for RVMD Earnings

July 4 at 2:35 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLC

July 3, 2025 | marketbeat.com

Revolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - Nasdaq

July 2, 2025 | nasdaq.com

Leerink Partnrs Issues Optimistic Estimate for RVMD Earnings

July 2, 2025 | marketbeat.com

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 30, 2025 | globenewswire.com

Lunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 29, 2025 | marketbeat.com

Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58

June 29, 2025 | americanbankingnews.com

Q3 EPS Estimate for Revolution Medicines Raised by Analyst

June 27, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Revolution Medicines' (RVMD) Buy Rating Reiterated at Guggenheim

June 25, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | Nasdaq

June 24, 2025 | nasdaq.com

Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What Happened

June 24, 2025 | marketbeat.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24, 2025 | reuters.com

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 24, 2025 | globenewswire.com

Revolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...

June 23, 2025 | finanznachrichten.de

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23, 2025 | globenewswire.com

SG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 22, 2025 | marketbeat.com

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

June 19, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, RVMD, LNTH, and BBIO Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.84 +0.05 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$16.74 -0.10 (-0.59%)

As of 07:56 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BridgeBio Pharma NASDAQ:BBIO

$43.50 -0.49 (-1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$44.28 +0.77 (+1.78%)

As of 07:06 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Lantheus NASDAQ:LNTH

$79.19 -1.23 (-1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$79.49 +0.30 (+0.38%)

As of 07:05 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$36.67 -1.20 (-3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$37.22 +0.56 (+1.51%)

As of 06:18 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time